BNXTF
Price
$0.62
Change
+$0.02 (+3.33%)
Updated
Oct 7 closing price
Capitalization
74.03M
TAK
Price
$14.10
Change
-$0.21 (-1.47%)
Updated
Oct 9, 03:32 PM (EDT)
Capitalization
45.75B
21 days until earnings call
Interact to see
Advertisement

BNXTF vs TAK

Header iconBNXTF vs TAK Comparison
Open Charts BNXTF vs TAKBanner chart's image
BIONXT SOLUTIONS
Price$0.62
Change+$0.02 (+3.33%)
Volume$100
Capitalization74.03M
Takeda Pharmaceutical
Price$14.10
Change-$0.21 (-1.47%)
Volume$10.39K
Capitalization45.75B
BNXTF vs TAK Comparison Chart in %
BNXTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BNXTF vs. TAK commentary
Oct 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNXTF is a Hold and TAK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 09, 2025
Stock price -- (BNXTF: $0.62 vs. TAK: $14.31)
Brand notoriety: BNXTF and TAK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BNXTF: 2% vs. TAK: 83%
Market capitalization -- BNXTF: $74.03M vs. TAK: $45.75B
BNXTF [@Pharmaceuticals: Generic] is valued at $74.03M. TAK’s [@Pharmaceuticals: Generic] market capitalization is $45.75B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BNXTF’s FA Score shows that 0 FA rating(s) are green whileTAK’s FA Score has 1 green FA rating(s).

  • BNXTF’s FA Score: 0 green, 5 red.
  • TAK’s FA Score: 1 green, 4 red.
According to our system of comparison, TAK is a better buy in the long-term than BNXTF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BNXTF’s TA Score shows that 3 TA indicator(s) are bullish while TAK’s TA Score has 3 bullish TA indicator(s).

  • BNXTF’s TA Score: 3 bullish, 5 bearish.
  • TAK’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BNXTF is a better buy in the short-term than TAK.

Price Growth

BNXTF (@Pharmaceuticals: Generic) experienced а -0.71% price change this week, while TAK (@Pharmaceuticals: Generic) price change was -2.92% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.66%. For the same industry, the average monthly price growth was +4.90%, and the average quarterly price growth was +63.90%.

Reported Earning Dates

TAK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.66% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TAK($45.8B) has a higher market cap than BNXTF($74M). BNXTF YTD gains are higher at: 144.383 vs. TAK (8.082). TAK has higher annual earnings (EBITDA): 1.13T vs. BNXTF (-4.93M). TAK has more cash in the bank: 419B vs. BNXTF (4.24K). BNXTF has less debt than TAK: BNXTF (7.06M) vs TAK (4.51T). TAK has higher revenues than BNXTF: TAK (4.48T) vs BNXTF (21.7K).
BNXTFTAKBNXTF / TAK
Capitalization74M45.8B0%
EBITDA-4.93M1.13T-0%
Gain YTD144.3838.0821,787%
P/E RatioN/A50.31-
Revenue21.7K4.48T0%
Total Cash4.24K419B0%
Total Debt7.06M4.51T0%
FUNDAMENTALS RATINGS
BNXTF vs TAK: Fundamental Ratings
BNXTF
TAK
OUTLOOK RATING
1..100
7961
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
3761
P/E GROWTH RATING
1..100
10037
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for BNXTF (76) in the null industry. This means that TAK’s stock grew significantly faster than BNXTF’s over the last 12 months.

TAK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BNXTF (100) in the null industry. This means that TAK’s stock grew similarly to BNXTF’s over the last 12 months.

TAK's SMR Rating (90) in the Pharmaceuticals Major industry is in the same range as BNXTF (100) in the null industry. This means that TAK’s stock grew similarly to BNXTF’s over the last 12 months.

BNXTF's Price Growth Rating (37) in the null industry is in the same range as TAK (61) in the Pharmaceuticals Major industry. This means that BNXTF’s stock grew similarly to TAK’s over the last 12 months.

TAK's P/E Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for BNXTF (100) in the null industry. This means that TAK’s stock grew somewhat faster than BNXTF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BNXTFTAK
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
37%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
52%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
50%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
48%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
41%
Advances
ODDS (%)
Bullish Trend 17 days ago
71%
Bullish Trend 9 days ago
43%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
44%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
44%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
BNXTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IYM151.571.55
+1.03%
iShares US Basic Materials ETF
CWB92.730.77
+0.84%
SPDR® Blmbg Convert Secs ETF
TRSY30.09N/A
N/A
Xtrackers US 0-1 Year Treasury ETF
RAYC18.37-0.01
-0.04%
Rayliant Quantamental China Equity ETF
BTA9.57-0.02
-0.21%
Blackrock Long-Term Municipal Advantage Trust

BNXTF and

Correlation & Price change

A.I.dvisor tells us that BNXTF and TAK have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNXTF and TAK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNXTF
1D Price
Change %
BNXTF100%
N/A
TAK - BNXTF
32%
Poorly correlated
-1.04%
SNOA - BNXTF
29%
Poorly correlated
-1.88%
SDZXF - BNXTF
29%
Poorly correlated
+3.96%
ALVO - BNXTF
13%
Poorly correlated
+0.46%
ESAIY - BNXTF
11%
Poorly correlated
-2.13%
More